The pathogenesis of cardiovascular (CV) mortality, whose rate is increased in type 2 diabetes, is poorly understood.While high serum adiponectin is associated with increased CV mortality in the general population, no data are available in type 2 diabetes.We here investigated whether this counterintuitive association was observable also in diabetic patients and whether it was sex-specific.
Methods:
Three prospective cohorts were analyzed: 1) Gargano Heart Study (GHS; 359 patients, 58 events/1,934 person-years; py); 2) Health Professional Follow-up Study (HPFS; 833 men, 146 events/10,024 py); 3) Nurses? Health Study (NHS; 902 women, 144 events/15,074 py).
Results:
In GHS serum adiponectin predicted CV mortality in men (hazard ratio, HR, and 95% CI per standard deviation, SD, increment?=?1.54, 1.19-2.01), but not women (HR?=?0.98, 0.48-2.01).Circulating adiponectin predicted CV mortality in men from HPFS (HR?=?1.44, 1.21-1.72), but not in women from NHS (HR?=?1.08, 0.86-1.35), used as replication samples. In a pooled analysis, HRs were 1.47 (1.27-1.70) in 1,075 men and 1.07 (0.86-1.33) in 1,019 women (p for HRs heterogeneity across sexes?=?0.018).
Conclusions:
This is the first report showing that high circulating adiponectin predicts increased CV mortality in men, but not in women with type 2 diabetes.
Further studies are necessary to unravel the mechanisms through which adiponectin influences CV mortality in a sex-specific manner.
Author: Claudia MenzaghiMin XuLucia SalveminiConcetta De BonisGiuseppe PalladinoTao HuangMassimiliano CopettiYan ZhengYanping LiGrazia FiniFrank B HuSimonetta BacciLu QiVincenzo Trischitta
Credits/Source: Cardiovascular Diabetology 2014, 13:130
Published on: 2014-09-10
Tweet
News Provider: 7thSpace Interactive / EUPB Press Office
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.